HANOVER, Md., Dec. 11, 2017 /PRNewswire/ -- Processa Pharmaceuticals, Inc. (the "Processa") (OTC PINK: PCSA), formed from the merger of Promet Therapeutics and Heatwurx Inc., is an emerging clinical stage biotech company focused on the development of drugs for the treatment of high unmet medical need conditions. Processa announced today that the Financial Industry Regulatory Association (FINRA) confirmed the below listed corporate actions requested by Processa:
Following the reverse split effective date, a letter "D" will be placed on the Company's trading symbol for 20 business days. The new symbol will be "PCSAD". The letter "D" will be removed in 20 business days and the trading symbol will revert back to "PCSA".
With the official name change to Processa Pharmaceuticals, Inc., Processa is also launching its website (http://www.processapharma.com) to assist individuals in following Processa's mission and products in development.
About PROCESSA
Processa Pharmaceuticals is an emerging clinical stage company focused on the development of drug products that are intended to improve the survival and/or the quality of life of patients who have a high unmet medical need condition. The company has assembled a proven management team, Board of Directors and product development team. The Processa team has over 25 years of experience developing drug products from IND enabling studies to NDA approvals while working on more than 50 drug development programs, including 30 FDA drug approvals.
For More Information:Investor Relations: Patrick Lin[email protected]925-638-3218Media: Mark Leonard[email protected]847-651-9682
Advertisement
- 1-7 Reverse Split
- Pre-Split Total Shares Outstanding: 246,907,902
- Post-Split Total Shares Outstanding: 35,272,557
- New Name: Processa Pharmaceuticals, Inc. (Previously Heatwurx, Inc.)
- New CUSIP: 74275C106
- Daily List Announcement Date: 12/7/2017
- Market Effective Date: 12/8/2017
Advertisement
Following the reverse split effective date, a letter "D" will be placed on the Company's trading symbol for 20 business days. The new symbol will be "PCSAD". The letter "D" will be removed in 20 business days and the trading symbol will revert back to "PCSA".
With the official name change to Processa Pharmaceuticals, Inc., Processa is also launching its website (http://www.processapharma.com) to assist individuals in following Processa's mission and products in development.
About PROCESSA
Processa Pharmaceuticals is an emerging clinical stage company focused on the development of drug products that are intended to improve the survival and/or the quality of life of patients who have a high unmet medical need condition. The company has assembled a proven management team, Board of Directors and product development team. The Processa team has over 25 years of experience developing drug products from IND enabling studies to NDA approvals while working on more than 50 drug development programs, including 30 FDA drug approvals.
For More Information:Investor Relations: Patrick Lin[email protected]925-638-3218Media: Mark Leonard[email protected]847-651-9682
View original content:http://www.prnewswire.com/news-releases/processa-pharmaceuticals-announces-reverse-stock-split-and-launches-new-website-300569472.html
SOURCE Processa Pharmaceuticals